Formycon, CoinAnalyst, Aixtron - Buy the dip

The asset class of the future

From a technical perspective, at least another drop into the correction range around USD 35,000 is possible for Bitcoin in the short term. The chart picture was too damaged for that after the sell-off at the beginning of the month. In the long term, Bitcoin is considered the inflation protection of the future, also due to its limitation of a maximum of 21 million units. In the long term, another positive is that even the savings bank, which is considered old-fashioned, wants to allow its customers to trade digital currencies such as Bitcoin and Ethereum. According to the plans, Sparkasse customers would be able to buy cryptocurrencies directly through their current accounts. An advantage over crypto-only exchanges, where new customers must first identify themselves.

Battered crypto companies

The rapid but painful correction of the digital reserve currency from USD 69,275 to the current level of around USD 47,000 has seen crypto-related stocks take an extreme beating. MicroStrategy, the Company with the highest holdings in the world, already sank 30%. Smaller companies also lost double-digit value, so the imagination for the future and the chance for a more significant rebound are more than given in the fluctuating world. One example is the young, highly innovative company CoinAnalyst, which celebrated its stock market debut in Frankfurt with highs around EUR 0.20. Although quite successful steps have been reported in recent weeks, the current share price is EUR 0.095, and the stock market value is still a manageable EUR 8.13 million.

The Canadian Big Data-based Company developed an artificial intelligence-based analytics platform that provides customers with access to a personalized dashboard that collects real-time data from the cryptocurrency market, such as coins, tokens and NFTs, from over 300 sources. It analyzes and evaluates them using Cogia AG's AI technology, which has been successful for years. In addition to the products "Insights" and "Crypto Market Letter", which is to appear globally in the future, the focus is primarily on the segment "Copy Trading". After the product's launch, which makes it possible to profit from trading experts and the AI-supported trading strategy, an average return of around 60% p.a. could be achieved. Based on the recent successes, the management plans to significantly increase capacity here.

In addition to the launch of a mobile app planned for the first quarter of 2022, the non-fungible tokens segment is also to be increased. For the next few years, CoinAnalyst's management sees tremendous growth ahead. After revenues amounted to CAD 0.9 million this year, CAD 17.09 million is already planned for 2023.

50% in one week

It is not only the crypto market that is currently experiencing high volatility. Investors in vaccine manufacturers such as BioNTech, Moderna and CureVac are also changing the color of their faces more often than not due to the rapidly changing price picture. At Formycon, a leading and independent developer of high-quality biopharmaceutical follow-on products, so-called biosimilars, it has become quiet. After a brilliant start to the year, the share was rippling along, with prices above EUR 75. However, at the beginning of December, the share marked a low for the year at EUR 42.50.

Two weeks later, the share price stands at EUR 60. The Martinsried-based Company announced a far-reaching cooperation for marketing the biosimilar FYB201, which offers further potential for the future. bioeq, licensee and exclusive holder of the worldwide marketing rights for the drug, had concluded an exclusive partnership with MS Pharma for the commercialization of FYB201 in the Middle East and North Africa.

Distribution agreements for FYB201 are already in place for the US market and Europe, among others. "Upon successful approval of FYB201, Formycon will participate in the commercialization revenues in all territories," the Company said.

Positive signs

At the equipment manufacturer for the production of compound semiconductors and nanomaterials, Aixtron AG, an end to the correction is not yet apparent. The broad support area at EUR 16 should provide compelling support; otherwise, the price is threatened with further trouble and a slide towards EUR 15.

Meanwhile, Morgan Stanley sent positive signals and initiated stock coverage with an "Equal Weight" rating and a price target of EUR 19. The analysts see the beginning of a multi-year growth cycle at Aixtron, driven by the topic of energy efficiency.

The crypto market is in a correction. Although the long-term outlook remains extremely positive, a further sell-off should not be ruled out. CoinAnalyst is positioning itself in the Big Data analytics space and has its finger on the pulse with its platform. Caution is still advised for Aixtron.